Content Specifications are intended to guide diplomates in selecting their MOC Part II and Part IV activities. They are not intended to be study guides for the MOC Part III exam, although the exams may include some questions on topics and references included in the Content Specifications. Please refer to the MOC Study Guides for exam preparation.

**New Validated Practical Knowledge**

I. Classification of pediatric interstitial lung disease

II. Eosinophilic esophagitis

III. Risk stratification in pediatric leukemias (especially ALL based on cytogenetic findings) and correlation with immunophenotyping

IV. Brain stem serotonergic abnormalities associated with sudden death syndrome

V. Placental pathology in cerebral palsy

VI. Villitis of unknown etiology

VII. Fetal thrombotic vasculopathy

VIII. Use of p57kip2 in differentiating complete from partial mole

IX. C4d in acute and chronic humoral rejection

X. Diagnosis and classification of pediatric vascular lesions using GLUT-1 and D2-40 immunohistochemical staining

XI. Diagnosis and classification of pediatric renal carcinoma
    Use of cytogenetics and TFE3/TFEB immunohistochemical staining

XII. Diagnosis of malignant rhabdoid tumor
    Use of cytogenetics and INI-1/BAF47 immunohistochemical staining

XIII. Use of calretinin staining in the diagnosis of Hirschsprung disease
XIV. Pediatric GIST tumors

XV. Perinatal – neonatal thrombosis

XVI. Genetic typing of pediatric brain tumors

Fundamental Knowledge

I. Perinatal/placental pathology

II. Pediatric leukemias and lymphomas

III. Hirschsprung disease, diagnostic criteria

IV. Complications of prematurity
   Chronic lung disease
   Necrotizing enterocolitis

V. Neonatal cholestasis, diagnostic criteria

VI. Pediatric transfusion medicine

VII. Approach to the congenitally abnormal fetus

VIII. Pediatric solid tumors
   Wilms tumor
   Neuroblastoma
   Ewing sarcoma
   Rhabdomyosarcoma

IX. Melanocytic skin lesions in children

REFERENCES


20. Kool M et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4
medulloblastomas. Acta Neuropathologica. Published online: 23 February 2012. DOI: 10.1007/s00401-012-0958.


